Submitted:
19 November 2026
Posted:
20 November 2026
You are already at the latest version
Abstract
The European Commission’s proposal COM(2026) 481 aims to strengthen cardiovascular prevention across the European Union through earlier risk detection, expanded population screening, and greater harmonisation among Member States. While its life-course perspective and focus on equitable access are commendable, this critical review—authored on behalf of the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR)—identifies key clinical and methodological limitations requiring refinement. First, evidence from WHO, ESC, and Cochrane syntheses indicates that broad population-level screening increases risk-factor detection without consistently reducing cardiovascular morbidity or mortality, risking resource diversion from high-risk patients. Second, grouping smoking, vaping, and smokeless nicotine use within a single behavioural assessment obscures substantial differences in toxicant exposure and cardiovascular risk profiles. We propose five evidence-based refinements: prioritising targeted, risk-stratified assessment over indiscriminate testing; evaluating programme success through risk-factor control and hard clinical outcomes rather than coverage targets; reserving second-line investigations for clinically indicated cases; embedding an actionable "identify–advise–treat–follow-up" smoking cessation pathway within cardiovascular health checks; and distinguishing continued exclusive smoking, dual use, complete substitution with non-combustible nicotine products, and nicotine initiation to guide proportionate clinical communication.
Keywords:
cardiovascular prevention
; European Union
; COM(2026) 481
; health policy
; smoking cessation
; tobacco harm reduction
; nicotine
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.